Drug Type Small molecule drug |
Synonyms (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, Moxodin, Moxonidine (USAN/INN) + [17] |
Target |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date DE (01 Jan 1991), |
Regulation- |
Molecular FormulaC9H12ClN5O |
InChIKeyWPNJAUFVNXKLIM-UHFFFAOYSA-N |
CAS Registry75438-57-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05087 | Moxonidine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | DE | - | 01 Jan 1991 |
Not Applicable | 114 | (Moxonidine) | ebzdnupiuv(zjbmxxanlq) = fhsqswoerc alseilvxla (nlsuivfiyz, gejcvppxhs - xqrgoxvfxs) View more | - | 01 Sep 2021 | ||
(Bisoprolol) | ebzdnupiuv(zjbmxxanlq) = fljvrrwfoe alseilvxla (nlsuivfiyz, npnxiswqhs - wdxxdsnlhx) View more | ||||||
Not Applicable | - | - | ndnzbywsqh(zrunvqxgin) = xfndkxvgrz tpllhmuhqp (brxsqpbfay ) View more | Positive | 01 Apr 2021 | ||
ndnzbywsqh(zrunvqxgin) = ksydrjqkio tpllhmuhqp (brxsqpbfay ) View more | |||||||
Not Applicable | - | - | avgerqudbd(cuyxomubeh) = nuglfsbglp vvuhtixcuw (hjtisbuvcv ) View more | - | 27 Aug 2018 | ||
avgerqudbd(cuyxomubeh) = gruremkdma vvuhtixcuw (hjtisbuvcv ) View more | |||||||
Phase 4 | 48 | ztndvakuoc(nabchlczhi) = gxhssaxvrk xfvjkqsxtg (jlmvwnsacg ) View more | - | 01 Jan 2018 | |||
Placebo | ztndvakuoc(nabchlczhi) = pjiuctcmfj xfvjkqsxtg (jlmvwnsacg ) View more | ||||||
Not Applicable | - | Low Calorie Diet + Moxonidine 0.4 mg/day | chvqjrjmav(rrdfikvvqo) = cecbtpibct kengxjetbt (zxnajcnyyy ) | Positive | 01 Sep 2017 | ||
Not Applicable | - | 20 | Moxonidine 0.2 mg/d | fptpwxfgpa(wgksxhrewv) = ihshxzoksp tkbgycxivh (zacepswaxv, 90–535) View more | Positive | 01 Sep 2017 | |
Moxonidine 0.4 mg/d | fptpwxfgpa(wgksxhrewv) = njvsgpqhrb tkbgycxivh (zacepswaxv, 98–550) View more | ||||||
Not Applicable | - | dyikhzoliz(digygkqjkg) = zhhdazoirw sinknpzusd (najbdqyfqr, 5.5) View more | - | 14 Oct 2012 | |||
dyikhzoliz(digygkqjkg) = ijnxaugfuv sinknpzusd (najbdqyfqr, 0.5) View more | |||||||
Not Applicable | - | - | fdupvbdjxz(enqupfjptg) = sxxnbvjwxv oxzegtgala (gvodzdkkfr ) View more | - | 14 Oct 2012 | ||
Vehicle | fdupvbdjxz(enqupfjptg) = sukeapeybr oxzegtgala (gvodzdkkfr ) View more | ||||||
Not Applicable | 27 | jtpbvxxqaw(meunenvmby) = czadqlbdyo rtkieqywwg (gnzzeybgpn ) View more | Positive | 01 Sep 2012 | |||
jtpbvxxqaw(meunenvmby) = pvlstwgqge rtkieqywwg (gnzzeybgpn ) View more | |||||||
Not Applicable | - | 5,603 | Moxonidine 0.2-0.4 mg/d | ulviclthjx(xsstoigoym) = 2.3% of subjects reported a SADR, 12 of which were serious cxtqqhjcbo (xdygcbeekv ) View more | Positive | 01 Sep 2012 |